We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

126 hedge funds and large institutions have $1.62B invested in Recursion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 10

382% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 11

132% more call options, than puts

Call options by funds: $2.03M | Put options by funds: $878K

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

50% more funds holding

Funds holding: 84 → 126 (+42)

28% more capital invested

Capital invested by funds: $1.26B → $1.62B (+$352M)

24.61% more ownership

Funds ownership: 34.53% → 59.14% (+25%)

Holders
126
Holders Change
+42
Holders Change %
+50%
% of All Funds
1.94%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
53
Increased
52
Reduced
10
Closed
11
Calls
$2.03M
Puts
$878K
Net Calls
+$1.16M
Net Calls Change
+$101K

Top Buyers

1
BlackRock
BlackRock
New York
+$94M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$64M
3
State Street
State Street
Massachusetts
+$56.7M
4
AI
ArchPoint Investors
Florida
+$23.6M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$23.3M

Top Sellers

1
CL
CRV LLC
California
-$16.9M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.6M
3
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
-$8.68M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.09M
5
AIM
ARK Investment Management
Florida
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
26
Samsara BioCapital
California
$9.24M -$4.02M -213,703 -28%
PC
27
PointState Capital
New York
$7.02M – – –
BAMCO Inc
28
BAMCO Inc
New York
$7M -$5.4M -287,237 -41%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$6.77M +$6.15M +327,113 +481%
N
30
Nuveen
North Carolina
$6.67M +$5.24M +278,323 +303%
Voloridge Investment Management
31
Voloridge Investment Management
Florida
$6.47M +$7.11M +377,717 New
Charles Schwab
32
Charles Schwab
California
$6.46M +$3.66M +194,467 +106%
Mitsubishi UFJ Trust & Banking
33
Mitsubishi UFJ Trust & Banking
Japan
$6.4M -$471K -25,030 -6%
NAMA
34
Nikko Asset Management Americas
New York
$6.32M -$756K -40,200 -10%
Sumitomo Mitsui Trust Group
35
Sumitomo Mitsui Trust Group
Japan
$6.32M -$756K -40,200 -10%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$6.29M +$4.96M +263,379 +253%
American Century Companies
37
American Century Companies
Missouri
$5.19M +$2.85M +151,692 +100%
PCM
38
Pentwater Capital Management
Florida
$4.8M +$282K +15,000 +6%
DFO
39
Duquesne Family Office
New York
$4.45M – – –
UBS Group
40
UBS Group
Switzerland
$4.44M +$3.54M +188,079 +264%
Citigroup
41
Citigroup
New York
$4.19M +$3.75M +199,063 +439%
AO
42
Allen Operations
New York
$3.73M +$2.81M +149,553 +220%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$3.52M +$1.66M +88,466 +75%
AG
44
Artal Group
Luxembourg
$3.43M – – –
Citadel Advisors
45
Citadel Advisors
Florida
$3.42M +$3.76M +199,607 New
AA
46
ALPS Advisors
Colorado
$3.16M +$3.47M +184,614 New
Bank of America
47
Bank of America
North Carolina
$2.93M +$2.72M +144,668 +546%
TRSOTSOK
48
Teachers Retirement System of the State of Kentucky
Kentucky
$2.82M – – –
JP Morgan Chase
49
JP Morgan Chase
New York
$2.68M +$2.35M +124,826 +395%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$2.61M +$2.35M +125,000 +458%
1
2
3 4 5

RXRX Hedge Fund Activity: Q4 2021 in Review

126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2021, worth a combined $1.62B — up 28% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new RXRX positions and 11 closed out — a net gain of 42 holders — while 52 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $94M. The largest seller was CRV LLC, exiting entirely with an estimated $16.9M sold.

  • 126 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2021, up from 84 in Q3 2021.
  • Funds reported $1.62B of Recursion Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
  • 53 funds opened new Recursion Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +42 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $94M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2021 was CRV LLC, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2021.